|Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’study|
HJN Andreyev, AR Norman, D Cunningham, J Oates, BR Dix, ...
British journal of cancer 85 (5), 692, 2001
|STAT proteins: from normal control of cellular events to tumorigenesis|
V Calò, M Migliavacca, V Bazan, M Macaluso, M Buscemi, N Gebbia, ...
Journal of cellular physiology 197 (2), 157-168, 2003
|The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of …|
A Russo, V Bazan, B Iacopetta, D Kerr, T Soussi, N Gebbia
Journal of clinical oncology 23 (30), 7518-7528, 2005
|Founder mutations in BRCA1 and BRCA2 genes|
R Ferla, V Calo, S Cascio, G Rinaldi, G Badalamenti, I Carreca, ...
Annals of Oncology 18 (suppl_6), vi93-vi98, 2007
|Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype|
V Bazan, M Migliavacca, I Zanna, C Tubiolo, N Grassi, MA Latteri, ...
Annals of Oncology 13 (9), 1438-1446, 2002
|miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells|
S Cascio, A D'Andrea, R Ferla, E Surmacz, E Gulotta, V Amodeo, V Bazan, ...
Journal of cellular physiology 224 (1), 242-249, 2010
|Ras family genes: an interesting link between cell cycle and cancer|
M Macaluso, G Russo, C Cinti, V Bazan, N Gebbia, A Russo
Journal of cellular physiology 192 (2), 125-130, 2002
|Male breast cancer|
L Ottini, D Palli, S Rizzo, M Federico, V Bazan, A Russo
Critical reviews in oncology/hematology 73 (2), 141-155, 2010
|Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia …|
V Bazan, V Agnese, S Corsale, V Calo, MR Valerio, MA Latteri, S Vieni, ...
Annals of oncology 16 (suppl_4), iv50-iv55, 2005
|Hereditary ovarian cancer|
A Russo, V Calò, L Bruno, S Rizzo, V Bazan, G Di Fede
Critical reviews in oncology/hematology 69 (1), 28-44, 2009
|Patterns of genomic instability in gastric cancer: clinical implications and perspectives|
L Ottini, M Falchetti, R Lupi, P Rizzolo, V Agnese, G Colucci, V Bazan, ...
Annals of Oncology 17 (suppl_7), vii97-vii102, 2006
|Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma|
G Bronte, S Rizzo, L La Paglia, V Adamo, S Siragusa, C Ficorella, ...
Cancer treatment reviews 36, S21-S29, 2010
|Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study|
B Iacopetta, A Russo, V Bazan, G Dardanoni, N Gebbia, T Soussi, D Kerr, ...
Annals of oncology 17 (5), 842-847, 2006
|Apoptosis: a relevant tool for anticancer therapy|
A Russo, M Terrasi, V Agnese, D Santini, V Bazan
Annals of Oncology 17 (suppl_7), vii115-vii123, 2006
|The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies|
LR Corsini, G Bronte, M Terrasi, V Amodeo, D Fanale, E Fiorentino, ...
Expert opinion on therapeutic targets 16 (sup2), S103-S109, 2012
|Breast cancer genome-wide association studies: there is strength in numbers|
D Fanale, V Amodeo, LR Corsini, S Rizzo, V Bazan, A Russo
Oncogene 31 (17), 2121, 2012
|Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations|
I Albanese, AG Scibetta, M Migliavacca, A Russo, V Bazan, RM Tomasino, ...
Biochemical and biophysical research communications 325 (3), 784-791, 2004
|Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?|
S Rizzo, G Bronte, D Fanale, L Corsini, N Silvestris, D Santini, G Gulotta, ...
Cancer treatment reviews 36, S56-S61, 2010
|Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies|
A Russo, V Bazan, V Agnese, V Rodolico, N Gebbia
Annals of Oncology 16 (suppl_4), iv44-iv49, 2005
|PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis|
F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ...
Oncotarget 7 (15), 19738, 2016